Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.56 |
| ▸ | TNKS | O95271 | 6/20 | 0.56 |
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.56 |
| ▸ | WNT3A | P56704 | 4/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.56 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.56 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.56 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315468 | 1.00 | TNKS2 (0.56) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL20286634 | 0.90 | TNKS2 (0.46) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL25932351 | 0.82 | TNKS2 (0.40) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL15672303 | 0.82 | TNKS2 (0.40) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL16206263 | 0.78 | TNKS2 (0.55) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL21097251 | 0.75 | TNKS2 (0.68) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL7783488 | 0.72 | TNKS2 (1.00) | TNKS2TNKSPARP1PARP2WNT3A | |
| SCHEMBL13729610 | 0.71 | KIF11 (0.52) | KIF11CHUKTXNRD1NOX4ADORA3 | |
| SCHEMBL16010695 | 0.71 | KCNK3 (0.50) | ADORA3 | |
| SCHEMBL16179473 | 0.70 | PDE4B (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966782-A2 | METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES | Tesaro, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| US-20250368739-A1 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) | ANAPTYSBIO, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4618997-A1 | COMPOSITIONS AND METHODS FOR IMPROVED CANCER TREATMENT | The Council of the Queensland Institute of Medical Research (AU) | 2025-09-24 | — | — | EP | disclosed |
| US-12415855-B2 | Methods of treating cancer with anti-PD-1 antibodies | TESARO, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12156872-B2 | Combination therapies for treating cancer | TESARO, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240226082-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TESARO, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024108256-A1 | COMPOSITIONS AND METHODS FOR IMPROVED CANCER TREATMENT | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024054898-A1 | ONVANSERTIB AND PARP INHIBITOR COMBINATION | CARDIFF ONCOLOGY, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4319729-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | Cardiff Oncology, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230416368-A1 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) | ANAPTYSBIO INC (US) | 2023-12-28 | — | — | US | disclosed |
| CN-115996726-A | Methods of treating cancer using combinations of PD-1 antagonists, radiochemical treatment and PARP inhibitors | 默沙东有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230111418-A1 | METHODS OF TREATING CANCER WITH ANTI-PD-1 ANTIBODIES | TESARO, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11622961-B2 | Combination therapies for treating cancer | TESARO, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| EP-4146275-A1 | METHODS OF TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, A CHEMORADIATION THERAPY AND A PARP INHIBITOR | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4077388-A1 | BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | Tesaro, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022217060-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220169734-A1 | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) | TESARO, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022090529-A1 | COMBINATION TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135670-A1 | ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF | TESARO, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220089739-A1 | Antibodies Directed Against Programmed Death-1 (PD-1) | ANAPTYSBIO, INC. | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622961-B2 | Combination therapies for treating cancer | PARP2, PARP1, PARP3 | TNKS2 15/4885TNKS 13/4885PARP1 2/4885 |
| US-20230111418-A1 | METHODS OF TREATING CANCER WITH ANTI-PD-1 ANTIBODIES | CD274, PDCD1LG2, PDCD1 | TNKS2 1270/4885TNKS 748/4885PARP1 101/4885 |
| US-12415855-B2 | Methods of treating cancer with anti-PD-1 antibodies | CD274, PDCD1LG2, PDCD1 | TNKS2 1270/4885TNKS 748/4885PARP1 101/4885 |
| US-20220135670-A1 | ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF | CD2, CD58, CD4 | TNKS2 2695/4885TNKS 3128/4885PARP1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.